Background
Despite an increase in its public awareness, colorectal cancer (CRC) remains one of the most common cancers and the second leading cause of cancer-related death globally [
1,
2]. Some genes involved in cell growth, survival, adhesion, invasion and angiogenesis have already been suggested to contribute to tumor progression in CRC [
3]. However, a full understanding of the key elements dictating the oncogenic phenotype as well as the molecular events supporting tumor progression undoubtedly helps discover new drugs and ways to prevent CRC.
The hippo signaling pathway is a highly conserved tumor suppressor pathway best known for its role in organ size regulation. The core kinase components MST1/2, WW45, LATS1/2, and MOB1 phosphorylate the downstream transcriptional co-activators YAP and TAZ [
4]. Growing evidence suggests that hippo pathway dysregulation is associated with CRC development [
5‐
8]. The gene that has received the most attention in the literature is YAP1, which was found to be involved in the development and progression of CRC [
5,
6,
9,
10]. The gene was reported to be overexpressed in 52.5% (73/139) of CRC, and the YAP1 protein was predominantly localized to the nucleus [
11]. In addition, YAP1 was considered as a prognostic factor for overall survival in CRC patients [
11].
In the present study, using high-resolution array comparative genomic hybridization (aCGH) and gene expression microarray, we identified genes that were differentially expressed among primary tumor, metastasis as well as normal colon mucosa samples, one of which was RASAL2. RASAL2 is a member of RAS GTPase-activating protein family (RAS GAP) that negatively regulates RAS by catalyzing the hydrolysis of RAS-GTP to RAS-GDP. The gene may exhibit pro-tumorigenic or anti-tumorigenic behavior depending on the cell context and/or type of stimulus in human cancers [
12‐
19]. Therefore, the functional role of RASAL2 in CRC was still unclear. Here, we studied the genetic alterations, clinical implications and biological effects of RASAL2 in CRC. In addition, we dissected the mechanistic role of the gene in LATS2/YAP1 activation, and the results suggested that RASAL2 promoted tumorigenesis and metastasis via activation of the hippo pathway through the LATS2/YAP1 axis.
Methods
CRC tissues
Primary and metastatic tumor and normal frozen tissues from 8 patients who underwent colectomy and/or metastasectomy at the Prince of Wales Hospital, Hong Kong were used for genomic studies (Additional file
1: Table S1). Archival formalin-fixed paraffin-embedded (FFPE) tissue specimens from 208 CRC patients who underwent colectomy at the same hospital between 1995 and 2014 were retrieved. All specimens were reviewed by an expert gastrointestinal pathologist (KFT) to confirm histological diagnosis and tumor cell content. Clinicopathological information was retrieved from the hospital database last updated in December 2015. The study was approved by Committees for Clinical Research Ethics of Joint Chinese University of Hong Kong-New Territories East Cluster.
Genomic studies
Microarray-based comparative genomic hybridization (array-CGH) analysis was performed using SurePrint G3 Human CGH Microarray Kit, 1 × 1 M (Agilent Technologies, Santa Clara, CA, USA). Gene expression array analysis was carried out by Macrogen (Seoul, South Korea).
RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated according to the protocol of TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA). Reverse transcription (RT) to synthesize complementary DNA (cDNA) was performed using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). The aliquots of cDNA were amplified using SYBR Green Master Mix (Thermo Fisher Scientific). β-actin was used as endogenous control. The RASAL2 and β-actin primers (Additional file
1: Table S2) were designed using Primer3web [
20,
21].
Immunohistochemistry and scoring
Immunohistochemistry (IHC) was performed on 5-μm sections from tissue microarray (TMA) blocks stained using anti-RASAL2 antibodies (ab121578, 1:400, Abcam, Cambridge, MA, USA) and anti-YAP1 antibodies (ab52771, 1:500, Abcam). The protein expression on the TMA slides was assessed using the histoscore (H-score) method.
Protein extraction and western blot analysis
Protein was extracted in ice-cold RIPA lysis buffer containing complete protease inhibitor cocktail tablets (Roche, Rotkreuz, Switzerland). RASAL2 was detected with a polyclonal anti- RASAL2 antibody (1:250, ab121578, Abcam). Anti-YAP1 antibody (1:20000, ab52771) was provided by Abcam. Other primary antibodies were from Cell Signaling (Danvers, MA, USA), including antibodies to LATS2 (1:1000, #5888S), phospho-YAP1 (S127) (1:1000, #4911) and Cyclin D1 (1:1000, #2926). β-actin (1:100000, A5441, Sigma-Aldrich, St. Louis, MO, USA) expression was used as an equal loading control. The secondary antibodies were anti-Mouse IgG-HRP (1:15000, 00049039, Dako, Agilent Technologies, Santa Clara, CA, USA) and anti-Rabbit IgG-HRP (1:5000, 00028856, Dako).
Cell culture, siRNAs /shRNAs and DNA plasmid
Immortalized human normal colon epithelial cells NCM460 [
22] and human CRC cell lines Caco2, CL-14, DLD-1, HCT 116, HT-29, LoVo, LS 180, SW480 and SW620 were used in this study. The NCM460 cell line was obtained from Dr. Jun YU [
23,
24] (Department of Medicine & Therapeutics, The Chinese University of Hong Kong), who purchased from INCELL Corporation LLC (San Antonio, TX, USA). The cell line was cultured using M3BaseTM medium (INCELL) with 10% FBS. Caco2, DLD-1, HCT 116, HT-29, LoVo, LS 180, SW480 and SW620 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). CL-14 cell line was obtained from Deutsche Sam lung von Mikroorganismen und Zellkulturen (Braunschweig, Germany). Constructs of ectopic RASAL2 expression, siRNAs, and shRNAs for RASAL2 knockdown can be found in the Additional file
1: Tables S2 and S3.
In vitro functional studies
Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenylte-trazolium bromide (MTT, Sigma-Aldrich) assay. For colony formation, transfected cells were cultured for 14 to 21 days, and then fixed with methanol and stained with 0.5% crystal violet. For soft agar assay, three milliliters of the transfected cell-agarose mixture were overlaid onto the base agarose. The plates were incubated for 3–4 weeks, and colonies were stained with 1 mg/ml p-iodonitrotetrazolium violet (INT, Sigma-Aldrich) for visualization. For cell cycle analysis, transfected cells were analyzed in a FACS Calibur Flow Cytometer and data was processed with CellQuest (BD Biosciences). Cell invasion and migration assays were analyzed using Biocoat Matrigel Invasion Chambers (Corning, Bedford, MA, USA) and sterilized transwell insert chambers (Corning), respectively. All experiments were performed in duplicate wells in n = 3 independent experiments and results were presented as mean ± SD.
In vivo tumorigenic assays
1 × 106 transfected CRC cells suspended in 100 μl PBS were injected subcutaneously into the dorsal region of anaesthetized nude mice (5 mice/construct, control in left and treatment in right). When tumor was formed, tumor diameter was recorded every three days for three consecutive weeks. At the end of investigation, mice were sacrificed and xenografts were then collected for diameter and weight measurements. All animal handling and experimental procedures were approved by the Department of Health of Hong Kong and the CUHK.
Double immunofluorescence staining
Cells grown on coverslips were fixed with 4% paraformaldehyde, permeated with 0.3% Triton X-100 and blocked with 1% BSA. Then cells were in turn incubated with a mixture of two primary antibodies (rabbit anti-YAP1, 1:500 and mouse anti-β-actin, 1:1000) at 4 °C overnight, as well as a mixture of secondary antibodies (Alexa Fluor 488 and 594, 1:2000, Thermo Fisher Scientific) in the dark for 1 h. Nuclei were counterstained by 4′,6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific). Images were captured using an Axio Imager2 microscope (Carl Zeiss, Germany).
Co-immunoprecipitation assay
Cells were transiently co-transfected with siRASAL2 and HA-Ubiquitin plasmids [
25]. Then the cells were kept in 20 μM MG132 (Calbiochem, Millipore, Billerica, MA, USA) for 4 h before protein collection. 500 μg cell lysate was incubated with a mixture of 50 μl Protein G bead and 5 μg conjugated antibody to YAP1 at 4 °C overnight with rotation. Finally, samples were loaded onto a SDS-PAGE gel for western blot analysis. Ubiquitination was detected with anti-HA-tag antibody (1:7000, ab9110, Abcam).
Half maximal inhibitory concentration (IC50) assay of verteporfin
The transfected cells were seeded into 96 well plates and starved for 24 h. Fresh medium with 2-fold diluted drug verteporfin concentration was added to each well. MTT assay was performed after incubation for 24 h.
Statistical analysis
All statistical analyses were performed in IBM SPSS Statistics (Version 19.0, IBM, Armonk, NY, USA). The expression levels between tumors and matched non-tumor tissues was analyzed using a paired Student’s t-test. An independent Student’s t-test was used to compare the mean expression value of any two pre-selected groups. A Pearson χ2 test was used to assess the association of target gene expression with the clinicopathological parameters. Pearson’s correlation coefficients were used to measure the correlation between two indices in clinical samples. The Kaplan-Meier method was used to plot the survival curves and the log-rank test was used to assess survival difference. Cox proportional hazard regression model was used to analyze independent prognostic factors. Two-tailed P-values of < 0.05 and those of < 0.01 were considered as statistically significant and highly statistically significant, respectively.
Discussion
This study showed, for the first time, that RASAL2 overexpression in CRC exerted 2 major effects: tumorigenesis and metastasis. Also, RASAL2 predicted poor disease outcomes independently, and RASAL2 promoted colon carcinogenesis through LATS2/YAP1 axis of hippo signaling pathway.
The RAS pathway is one of the most deregulated signaling pathways in human cancer [
37] . The RAS family proteins are small molecule GTPases that relay extracellular signals to intracellular effector pathways. The guanine nucleotide exchange factors (GEFs) and the GTPase activating proteins (GAPs) serve as two key modulators that regulate the activity of RAS GTPases [
38] . So far a total of 14 RAS GAP genes have been identified in human genome [
39]. RASAL2 was initially identified as a tumor suppressor [
40] and the inactivation of RASAL2 promoted tumor progression and metastasis in luminal B breast, ovarian, and lung cancers [
13,
15,
16]. However, other studies found that RASAL2 promoted mesenchymal invasion and metastasis [
14,
17‐
19]. A genome-wide study revealed that RASAL2 depletion inhibits cancer cell growth and invasiveness in liver and triple-negative breast cancers [
14,
17]. Feng et al [
14] reported a pro-oncogenic role of RASAL2 in triple-negative breast cancer. Their studies demonstrated that RASAL2 promoted mesenchymal invasion and metastasis through activating RAC1 signaling pathway independent of its RAS GAP catalytic activity. They also showed that RASAL2 was a functional target of anti-invasive mircroRNA-203, and RASAL2 expression was associated with poor clinical outcome, early metastasis and disease recurrence in patients with triple-negative breast cancer [
14]. This is similar to our finding that RASAL2 played an oncogenic role in CRC tumorigenesis in vitro and in vivo, regardless of
KRAS/NRAS mutation status.
Our findings appear to contradict a previous finding that RASAL2 was a tumor suppressor whose downregulation resulted in increased tumor growth, progression and metastasis in CRC [
41]. Jia et al found that RASAL2 gene expression was negatively correlated with International Federation of Gynecology and Obstetrics (FIGO) stage [
41]. However, in other cohorts like TCGA and GENT, RASAL2 consistently showed upregulation in CRC, and that is consistent with our results. Also, RASAL2 copy number gain was found in other gastrointestinal cancers, such as gastric, liver and pancreas cancer, in TCGA.
We found that RASAL2 was involved in hippo pathway in both
KRAS/NRAS mutant and wild-type CRC cell lines. The core kinase-signaling cassette and downstream effectors of mammalian hippo pathway are highly conserved [
42], including MST 1/2, SAV1, LATS 1/2, YAP1 and TAZ [
43]. Activated MST1/2 interacts with SAV1 via the SARAH domains presented on both proteins, leading to phosphorylation and activation of direct substrates LATS1/2 [
44]. YAP1 is a negatively regulated downstream target of the hippo signaling pathway. The mammalian ortholog of hippo kinase LATS2 suppresses the oncogenic activity of YAP1 oncogene by promoting YAP1 (Ser127) phosphorylation and subsequent cytoplasmic retention. Most of the known genes involved in the hippo signaling pathway are deregulated in human cancers and their expression levels as well as activities are correlated with tumor development and progression. Expression studies of common hippo signaling pathway components in CRC were also reported [
6,
7,
45]. But the mechanism by which the hippo pathway is regulated is largely unknown. One of our key findings was that we identified RASAL2 as a novel regulator of the hippo pathway in colorectal tumorigenesis. In our study, we extracted the gene activation signatures of LATS2 and YAP1 from microarray data and performed western blot in RASAL2-downregulated CRC cells. RASAL2 accelerates CRC cell growth through interaction with LATS2-YAP1. The interaction between RASAL2 and YAP1 led to YAP1 dephosphorylation and nuclear translocation, thus preventing YAP1 from ubiquitination in the cytoplasm and functioning as a transcriptional co-activator to stimulate expression of pro-proliferation genes like CCND1 in CRC.
YAP1, the gene that received the most attention in the hippo signaling pathway, was found to be upregulated in CRC. However, YAP1 under-expression has also been observed in breast [
46] and CRC [
47] before. YAP1 is present in the nucleus and cytoplasm. Thus, both expression level and intracellular location of YAP1 must be considered when it is used as a biomarker. Our study further provided evidence for the constitutive interaction between RASAL2 and nuclear YAP1 in human CRC samples by IHC, therefore targeting the LATS2/YAP1 axis via RASAL2 may be more effective for the treatment of CRC in clinical settings. Previous studies showed that nuclear YAP1 was independently predictive of poor prognosis in 1028 CRC patients [
48], and we verified that nuclear YAP1 was a predictor for worse survival in our cohort of 208 CRC patients (Additional file
2: Figure S6). But unlike RASAL2, nuclear YAP1 expression could not independently predict prognosis by multivariate cox regression analysis for our CRC patients (
P = 0.609, Additional file
1: Table S8).
In addition to its role in tumorigenesis, RASAL2 induced tumor invasion and metastasis. When comparing the RASAL2 mRNA expression levels among normal colon mucosa, primary tumors and metastatic tumors, we found that metastatic tumors showed the highest RASAL2 expression, followed by primary tumors, and then normal colon mucosa. We also found that overexpression of RASAL2 was significantly associated with advanced tumor stages (III/IV) as well as lymphatic and distant metastases of CRC patients. RASAL2 knockdown in CRC cell lines also inhibited cell migration and invasion properties in vitro. We revealed that RASAL2 did not disturb the epithelial-mesenchymal transition (EMT) expression in CRC. Similarly, Feng et al [
14] found that RASAL2 regulated mesenchymal invasion, without affecting EMT. Nevertheless, RASAL2 was reported to regulate EMT process in lung [
15] and ovarian cancers [
16] previously. Given the complexity and heterogeneity of molecular cancer pathways, it is not so surprising that such paradoxes exist in human cancers.